Cefaclor is a 2nd generation cephalosporin which has been in use for over 20 years. It is active against basic pathogens invading respiratory tract. Although, the resistance of micro-organisms responsible for airways infections to cefaclor differs greatly from country to country, many clinicians emphasise its effectiveness in the treatment of pharyngitis, tonsillitis, otitis media, sinusitis and bronchitis necessitating the use of antibiotic. Beyond that, approved therapeutic indications for the use of cefaclor include the infections of urinary tract, skin and soft tissues. Cefaclor has favourable pharmacodynamic profile. Its bioavailability exceeds 90%. It is also associated with few side effects. Current data suggest that cefaclor has a low tachyphylactic potential.

Keywords: upper respiratory tract, antibioticotherapy, Cefaclor